Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category.
Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic form of dementia from UK biotech AviadoBio for around $50 million.
